3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
4
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Advanced Cancer
3
Uveal Melanoma
2
Recurrence
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Liver Neoplasms
2
Hodgkin Disease
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Various Advanced Cancer
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Sarcoma
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Site
1
Microsatellite Unstable Colorectal Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Interventions
Oxaliplatin
5
Capecitabine
5
Cisplatin
4
Paclitaxel
3
Fluorouracil
3
camrelizumab
2
apatinib
2
S 1 (combination)
2
Leucovorin
2
Docetaxel
2
titanium silicide
1
rucaparib
1
relatlimab
1
pazopanib
1
linrodostat
1
ezogabine
1
endostar protein
1
dacomitinib
1
capivasertib
1
Sunitinib
1
Nivolumab
1
Metabolic Networks and Pathways
1
Irinotecan
1
Ipilimumab
1
Everolimus
1
Epirubicin
1
Electroporation
1
Drug Therapy, Combination
1
Drug Therapy
1
Congresses as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Gastric Cancer
×
relatlimab
×
Clear all
NCT02935634
2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2
Completed
190 enrolled
25 charts